Single-port (SP) robotic systems have the benefits of fully wristed three-dimensional high-definition cameras and multi-jointed wristed instruments. However, SP robotic pancreatic surgery (SPRPS) is seldom reported due to its intricacy and technological difficulties. Utilizing the brand-new da Vinci SP system, researchers for a study sought to assess the viability of SPRPS.

Between December 24, 2021, and February 23, 2022, a series of patients who had pancreaticoduodenectomy, distal pancreatectomy, and SP robotic pancreatic enucleation were examined for demographics and short-term results.

The research involved 23 patients (8 men and 15 women; mean age, 39.7 years). About 11 patients received SP robotic pancreatic enucleation, 11 got SP robotic distal pancreatectomy, and 1 underwent SP robotic pancreaticoduodenectomy. The median estimated blood loss was 40.0 (interquartile range, 20.0-50.0) mL, and the mean operating duration was 156.5 minutes. No patient required blood transfusions or conversion to laparotomy. One patient from each of the 3 groups suffered an abdominal infection and grade B postoperative pancreatic fistula (POPF), but they all fully recovered with conservative care. No patient experienced serious problems (Clavien grade≥ 3), pancreatectomy hemorrhage, or grade C POPF after surgery. The typical hospital stay following surgery was four days. The majority of the tumors were benign, according to a pathological evaluation, and their mean biggest dimension was 2.8 cm.

In certain patients, SPRPS with the da Vinci SP system was safe & practical. However, the indications for SPRPS require further investigation and surgical practice.